GliaPharm is developing novel compounds that target glia-mediated pathways to provide neuroprotection and support cognitive function in individuals with neurological and psychiatric disorders. By focusing on the essential roles of glial cells, the company aims to create a new class of medicines that address the unmet needs in brain health.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for neurological and psychiatric disorders primarily focus on neurons, often overlooking the critical role of glial cells in brain health. This neuron-centric approach may leave unmet needs in addressing the underlying causes of impaired neuroprotection and cognitive function. Many brain disorders are characterized by deficient brain energetics.
Solution
GliaPharm is developing a new class of medicines that target glia-mediated pathways to enhance neuroprotection and support cognitive function. By focusing on glial cells, which outnumber neurons and play essential roles in neuronal metabolic support, neuroprotection, brain homeostasis, and neuroinflammation, GliaPharm aims to increase the energy available to the brain. GliaPharm's drug candidates target metabolic pathways in astrocytes, a type of glial cell, to improve neuronal performance. This approach has the potential to positively impact a range of conditions characterized by deficient brain energetics.
Target Audience
The primary target audience includes individuals with neurological and psychiatric disorders, as well as researchers and clinicians focused on brain health and neurodegenerative diseases.
Features
- Novel drug candidates targeting glia-mediated pathways
- Focus on enhancing brain energy by targeting metabolic pathways in astrocytes
- GliaX™ technology platform for discovering and developing clinical applications by targeting glial cells
- Development of specific cell therapies to treat neurological diseases in collaboration with Universities of Bern and Lausanne
- 3D culture method using brain organoids from mouse and human-derived cells in collaboration with HEPIA